REGENXBIO Reports Q3 2025 Financial and Operational Progress

RegenXBio Inc. ( (RGNX) ) has released its Q3 earnings. Here is a breakdown of the information RegenXBio Inc. presented to its investors.

REGENXBIO Inc. is a biotechnology company specializing in the development of gene therapies for rare and retinal diseases, leveraging its proprietary AAV gene therapy platform to deliver one-time treatments.

In its third-quarter 2025 earnings report, REGENXBIO highlighted significant progress in its late-stage gene therapy programs, including advancements in treatments for Duchenne muscular dystrophy, MPS II, and chronic retinal diseases. The company also reported financial results, showcasing an increase in revenue and cash position compared to the previous year.

Key financial metrics revealed a revenue increase to $29.7 million from $24.2 million in the same quarter last year, driven by development service revenue under a partnership with Nippon Shinyaku. The company’s cash and marketable securities rose to $302 million, primarily due to upfront payments and royalty monetization. However, REGENXBIO reported a net loss of $61.9 million, slightly higher than the previous year’s loss.

Strategically, REGENXBIO is advancing its RGX-202 program for Duchenne muscular dystrophy, with pivotal trial enrollment completed and topline results expected in early 2026. The company is also on track with its RGX-121 program for MPS II, anticipating an FDA decision in early 2026, and is progressing with its sura-vec program for retinal diseases, with pivotal trial enrollments completed.

Looking ahead, REGENXBIO remains optimistic about its potential to become a commercial entity by early next year, supported by its robust pipeline and strategic partnerships. The company anticipates further milestones in its gene therapy programs, which could significantly impact its financial and operational trajectory.